Lyell Immunopharma has raised $493 million across early seed and large-stage financing, including seed backing (2018), a Series C led by GSK (Mar 12, 2020) for expanded R&D, and a $100M Post-IPO tranche on July 25, 2025. Founded in 2018, Lyell advances engineered cell therapies CAR-T and TIL approaches ttargeting solid tumors and hematologic disease. Funding supported translational research,